Will Lewis

Insmed Inc (NASDAQ:INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launches that could shape the company's growth over the next 18 months. • Insmed stock is gaining...

In an email to the Washington Post’s newsroom leaders, billionaire owner Jeff Bezos assured that the newspaper’s ethical standards will remain unchanged despite recent controversies surrounding its CEO and an incoming senior editor. What Happened: Bezos, the founder of Amazon.com, in an...

It was a good month for Insmed Incorporated (NASDAQ: INSM). On Sept. 5, the company released positive phase 3 data for ALIS in the treatment of nontuberculous mycobacterial lung disease, inspiring a doubling in stock price and “elation” in the long-toiling staff. “This data...